ArticleCancers2025
Early-Stage Melanoma Benchmark Dataset.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI Dermatology's Unfulfilled Promise: Why Early Melanoma Detection Remains Unverified.International journal of dermatology · 2026Article
- Translating Features to Findings: Deep Learning for Melanoma Subtype Prediction.Dermatopathology (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe early detection of melanoma is crucial for improving patient outcomes, as survival rates decline dramatically with disease progression. Despite significant achievements in deep learning methods for skin lesion analysis, several challenges limit their effectiveness in clinical practice. One of the key issues is the lack of knowledge about the melanoma stage distribution in the training data, raising concerns about the ability of these models to detect early-stage melanoma accurately. Additionally, publicly available datasets that include detailed information on melanoma stage and tumor thickness remain scarce, restricting researchers from developing and benchmarking methods specifically tailored for early diagnosis. Another major limitation is the lack of cross-dataset evaluations. Most deep learning models are tested on the same dataset they were trained on, so they fail to assess their generalization ability when applied to unseen data. This reduces their reliability in real-world clinical settings.
methodsWe introduce an early-stage melanoma benchmark dataset to address these issues, featuring images labeled according to T-category based on Breslow thickness.
resultsWe evaluated several state-of-the-art deep learning models on this dataset and observed a significant drop in performance compared to their results on the ISIC Challenge datasets.
conclusionsThis finding highlights the models' limited capability in detecting early-stage melanoma. This work seeks to advance the development and clinical applicability of automated melanoma diagnostic systems by providing a resource for T-category-specific analysis and supporting cross-dataset evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.